What does this research mean for the field?

Combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors generally increases toxicity, necessitating adjustments in treatment protocols. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

The aim is to assess the safety of combining radiotherapy with specific targeted agents including EGFR, ALK, and BRAF/MEK inhibitors.

March 2, 2026Open Access

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors

Key Points

The aim is to assess the safety of combining radiotherapy with specific targeted agents including EGFR, ALK, and BRAF/MEK inhibitors.
Consensus statements developed by ESMO and ESTRO experts
Evaluation of scenarios for drug interruptions or dosage reductions
Assessment of radiotherapy adaptation strategies.
Increased toxicity is likely when combining treatments
Recommendations for drug interruption or reduction to manage risks
Advocacy for significant adjustments in radiotherapy protocols.

Abstract

For most scenarios, concurrently combining RT with targeted agents may lead to increased toxicity. Therefore, we recommend a drug interruption, a drug dosage reduction, or a major RT adaptation in various scenarios.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Aken et al. (Thu,) studied this question.

synapsesocial.com/papers/69a528b3f1e85e5c73bf031e https://doi.org/https://doi.org/10.1016/j.esmoop.2026.106076

Bookmark

View Full Paper